Holiday shipping dates:
Last international orders dispatched: Friday 11th December
Last UK domestic orders dispatched: Wednesday 16th December
Following the holiday period, shipping will resume as normal from the week commencing Monday 4th January 2027
Glioblastoma WHO IV cell line, NCH417
| Inventor | Institute |
|---|---|
| Christel Herold-Mende | Heidelberg University |
| SKU: | 162317 |
|---|---|
| Product description: | NCH417 is a patient-derived IDH wildtype glioblastoma cell line established from a primary WHO grade IV tumour resected from a 69 year old male patient. Cells grow as adherent monolayer cultures under standard conditions. |
| Production details: | Patient-derived cell line established from human tumour tissue obtained during surgical resection and expanded in vitro. |
| Cat. #: | 162317 |
|---|---|
| Cancer types: | Brain cancer |
| Organism: | Human |
| Tissue: | Brain |
| Morphology: | Adherent |
| Growth properties: | Cells grow as adherent monolayer cultures under standard culture conditions at 37°C in a humidified incubator with 5% CO2. Medium is replaced twice per week. |
| Primary citation: | Wirthschaft et al. Acta Neuropathol. 138(2):275-293. PMID: 31062076. |
| Growth medium: | DMEM (high glucose) supplemented with 10% fetal calf serum (FCS), 1% GlutaMAX, and 1% penicillin/streptomycin. |
|---|---|
| Subculture routine: | Cells are passaged at sub-confluent densities using 0.05% Trypsin-EDTA. After enzymatic detachment, trypsin is neutralised with serum-containing medium and cells are reseeded into fresh culture vessels. Passage number should be recorded. |
| Temperature: | 37°C |
| References: |
Wirthschaft et al. 2019. Acta Neuropathol. 138(2):275-293. PMID: 31062076. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.